Antiviral resistance among influenza A viruses is associated with high morbidity and mortality in immunocompromised hosts. However, treatment strategies for drug-resistant influenza A are not established. A triple-combination antiviral drug (TCAD) regimen consisting of amantadine (AMT), oseltamivir (OSL) and ribavirin (RBV) demonstrated good efficacy in an animal model.
Methods
We first analysed the pharmacokinetics (PKs) of TCAD therapy in healthy volunteers. We then performed a pilot study of TCAD therapy in patients undergoing chemotherapy or haematopoietic cell transplantation. AMT (75 mg), OSL (50 mg) and RBV (200 mg) were administered three times a day for 10 days. The safety and PKs of TCAD therapy were monitored.
Results
The PKs of TCAD therapy in healthy volunteers was shown to be similar to the PKs of each drug individually from a single dose. In the pilot study, six immunocompromised patients received TCAD therapy and one patient received OSL monotherapy. All but one patient completed 10 days of TCAD therapy without side effects; one patient receiving TCAD was withdrawn from the study because of respiratory failure and ultimately recovered. Viral load was decreased after TCAD therapy, despite the presence of either AMT- or OSL-resistant virus in two cases. One patient with 2009 influenza A/ H1N1 receiving OSL monotherapy developed confirmed OSL resistance during treatment.
Conclusions
TCAD therapy had similar PKs to each individual antiviral during monotherapy following a single dose and can be administered safely in immunocompromised patients.
References
1.
CasperC., EnglundJ., BoeckhM.How I treat influenza in patients with hematologic malignancies. Blood2010; 115: 1331–1342.
2.
NicholsW.G., GuthrieK.A., CoreyL., BoeckhM.Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis2004; 39: 1300–1306.
3.
ChemalyR.F., GhoshS., BodeyG.P.Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore)2006; 85: 278–287.
4.
KunisakiK.M., JanoffE.N.Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis2009; 9: 493–504.
5.
LjungmanP., de la CamaraR., Perez-BercoffL.Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica2011; 96: 1231–1235.
6.
ChoiS.M., BoudreaultA.A., XieH.Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood2011; 117: 5050–5056.
7.
Espinosa-AguilarL., GreenJ.S., ForrestG.N.Novel H1N1 influenza in hematopoietic stem cell transplantation recipients: two centers’ experiences. Biol Blood Marrow Transplant2011; 17: 566–573.
8.
BautistaE., ChotpitayasunondhT., GaoZ.Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med2010; 362: 1708–1719.
9.
NicholsonK.G., AokiF.Y., OsterhausA.D.Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet2000; 355: 1845–1850.
10.
TreanorJ.J., HaydenF.G., VroomanP.S.Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA2000; 283: 1016–1024.
11.
MosconaA.Global transmission of oseltamivir-resistant influenza. N Engl J Med2009; 360: 953–956.
12.
van der VriesE., SchuttenM., BoucherC.A.The potential for multidrug-resistant influenza. Curr Opin Infect Dis2011; 24: 599–604.
HurtA.C., ChotpitayasunondhT., CoxN.J.Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis2012; 12: 240–248.
15.
NguyenH.T., FryA.M., LovelessP.A., KlimovA.I., GubarevaL.V.Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/ I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis2010; 51: 983–984.
16.
van der VriesE., StelmaF.F., BoucherC.A.Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med2010; 363: 1381–1382.
17.
KisoM., MitamuraK., Sakai-TagawaY.Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet2004; 364: 759–765.
NguyenJ.T., HoopesJ.D., LeM.H.Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS ONE2010; 5: e9332.
20.
NguyenJ.T., SmeeD.F., BarnardD.L.Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses. PLoS ONE2012; 7: e31006.
21.
HoopesJ.D., DriebeE.M., KelleyE.Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus. PLoS ONE2011; 6: e29778.
22.
NguyenJ.T., HoopesJ.D., SmeeD.F.Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother2009; 53: 4115–4126.
23.
US Department of Health and Human Services FDA, Center for Drug Evaluation and Research (CDER).Guidance for industry; statistical approaches to establishing bioequivalence. (Updated January 2001. Accessed 10 March 2013.) Available from http://www.fda.gov/downloads/Drugs/Guidances/ucm070244.pdf.
24.
US Department of Health and Human Services FDA, Center for Drug Evaluation and Research (CDER).Guidance for industry; bioavailability and bioequivalence studies for orally adimistered products – general considerations. (Updated March 2003. Accessed 10 March 2013.) Available from http://www.fda.gov/downloads/Drugs/…/Guidances/ucm070124.pdf.
25.
DuweS., SchweigerB.A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. J Virol Methods2008; 153: 134–141.
26.
CampbellA.P., JacobS.T., KuypersJ.Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell transplant recipient: detection of extrapulmonary H1N1 RNA and use of intravenous peramivir. Ann Intern Med2010; 152: 619–620.
27.
CDC.Oseltamivir-resistant novel influenza A. (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. (Updated 14 August 2009. Accessed 10 March 2013.) Available from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm58d0814a1.htm.
28.
DuvalX., van der WerfS., BlanchonT.Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med2010; 7: e1000362.
29.
IlyushinaN.A., HoffmannE., SalomonR., WebsterR.G., GovorkovaE.A.Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther2007; 12: 363–370.
30.
SmeeD.F., WongM.H., BaileyK.W., SidwellR.W.Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir Chem Chemother2006; 17: 185–192.
31.
SimeonovaL., GegovaG., GalabovA.S.Prophylactic and therapeutic combination effects of rimantadine and oseltamivir against influenza virus A (H3N2) infection in mice. Antiviral Res2012; 95: 172–81.
32.
KimW.Y., Young SuhG., HuhJ.W.Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother2011; 55: 5703–5709.
33.
MorrisonD., RoyS., RaynerC.A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS ONE2007; 2: e1305.
TranD., ScienceM., DixD.Pandemic (H1N1) 2009 influenza in Canadian pediatric cancer and hematopoietic stem cell transplant patients. Influenza Other Respi Viruses2012; 6: e105–e113.
36.
PerelsonA.S., RongL., HaydenF.G.Combination antiviral for influenza: predictions from modeling of human infections. J Infect Dis2012; 205: 1642–1645.
